AccurEdit Therapeutics (Suzhou) Co., Ltd., a leading gene editing therapy specialist based in China, has published the efficacy and safety data for its drug candidate ART001, which is being investigated as a treatment for transthyroxine protein amyloidosis. ART001, the first non-viral vector in vivo gene-edited drug in China to enter investigator-initiated trials, has shown promising safety and efficacy through 24 weeks of clinical observation, positioning it as a potential “Best in Class” drug.
The drug is currently under clinical review in China, and preparations are underway for a clinical filing in the U.S. market.- Flcube.com
